2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $11B | $11B | $12B | $12B | $12B |
Cost of Revenue | $8B | $8B | $8.7B | $9B | $8.7B |
Gross Profit | $3.1B | $3.2B | $2.8B | $3.3B | $3.3B |
Gross Profit % | 28% | 28% | 25% | 27% | 28% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $842M | $1.3B | $888M | $683M | $347M |
Dep. & Amort. | $389M | $388M | $375M | $370M | $401M |
Def. Tax | $247M | $33M | -$26M | -$26M | $0 |
Stock Comp. | $59M | $64M | $26M | $79M | $31M |
Chg. in WC | $313M | -$298M | -$218M | -$816M | $131M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $553M | $79M | $83M | $93M | $78M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $553M | $79M | $83M | $93M | $78M |
Receivables | $861M | $794M | $867M | $953M | $872M |
Inventory | $1.4B | $1.7B | $2B | $2.2B | $2.1B |
Conagra is not providing fiscal 2026 guidance until July due to ongoing macroeconomic volatility, but highlighted strong consumer demand, ongoing inventory rebuilds, and continued monitoring of inflation, tariffs, and consumer sentiment as key factors.
Q3 performance was consistent with expectations, with strong overall consumption trends, though some channel-specific weakness was noted in convenience stores and certain areas of the dollar channel.
Free cash flow conversion was 125% in Q3, with $500 million of debt paid down in the last twelve months; strong cash flow is expected to continue, with debt paydown remaining a priority and leverage target updates coming in July.
CapEx guidance for the current year was lowered by $40 million due to timing shifts, not cuts; higher CapEx is expected next year as delayed projects move forward, including ongoing supply chain modernization and plant upgrades.
Gross margins are expected to improve in Q4 versus Q3 as supply disruptions ease and service levels improve, but inflation remains elevated at 4% and external cost pressures (e.g., tariffs, input costs) are being closely monitored for potential impact on future results.